Drug reference

Insulin aspart

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 774, 775

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

FIASP ® Diabetes mellitus ▶BY SUBCUTANEOUS INJECTION ▶Child 1–17 years: Administer immediately before meals or when necessary shortly after meals, according to requirements ▶Adult: Administer immediately before meals or when necessary shortly after meals, according to requirements ▶BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Child 1–17 years: According to requirements ▶Adult: According to requirements NOVORAPID ® Diabetes mellitus ▶BY SUBCUTANEOUS INJECTION ▶Child: Administer immediately before meals or when necessary shortly after meals, according to requirements ▶Adult: Administer immediately before meals or when necessary shortly after meals, according to requirements ▶BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Child: According to requirements ▶Adult: According to requirements l UNLICENSED USE ▶In children Not licensed for use in children under 1 year.

PDF page 774

National Funding Access Decisions

NICE decisions ▶Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151 Continuous subcutaneous insulin infusion is recommended as an option in adults and children 12 years and over with type 1 diabetes: . who suffer repeated and unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or . whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple- injection regimens (including the use of long-acting insulin analogues where appropriate). Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years. www.nice.org.uk/guidance/ta151 Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (April 2017) that insulin aspart (Fiasp ®) is accepted for use within NHS Scotland for the treatment of diabetes mellitus in adults.

PDF page 775

Safety

Interactions

→Appendix 1: insulins

PDF page 774

Side Effects

▶Common or very common Skin reactions ▶Uncommon Refraction disorder

PDF page 774

Pregnancy

Not known to be harmful—may be used during pregnancy.

PDF page 774

Breast Feeding

Not known to be harmful—may be used during lactation.

PDF page 774

Dose and formulations

Directions For Administration

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team. ▶With intravenous use in adults For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to 0.05-1 unit/mL with infusion ﬂuid; adsorbed to some extent by plastics of infusion set. ▶With intravenous use in children For intravenous infusion, dilute to a concentration of 0.05–1 unit/mL with Glucose 5% or Sodium Chloride 0.9% and mix thoroughly; insulin may be adsorbed by plastics, ﬂush giving set with 5 mL of infusion ﬂuid containing insulin.

PDF page 774

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Fiasp (Novo Nordisk Ltd) A Insulin aspart 100 unit per 1 ml Fiasp 100units/ml solution for injection 10ml vials | 1 vial P £14.08 DT = £14.08 ▶Fiasp FlexTouch (Novo Nordisk Ltd) A Insulin aspart 100 unit per 1 ml Fiasp FlexTouch 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £30.60 DT = £30.60 ▶Fiasp Penfill (Novo Nordisk Ltd) A Insulin aspart 100 unit per 1 ml Fiasp Penfill 100units/ml solution for injection 3ml cartridges | 5 cartridge P £28.31 DT = £28.31 ▶NovoRapid (Novo Nordisk Ltd) Insulin aspart 100 unit per 1 ml NovoRapid 100units/ml solution for injection 10ml vials | 1 vial P £14.08 DT = £14.08 ▶NovoRapid FlexPen (Novo Nordisk Ltd) Insulin aspart 100 unit per 1 ml NovoRapid FlexPen 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £30.60 DT = £30.60 ▶NovoRapid FlexTouch (Novo Nordisk Ltd) Insulin aspart 100 unit per 1 ml NovoRapid FlexTouch 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £32.13 DT = £30.60 ▶NovoRapid Penfill (Novo Nordisk Ltd) Insulin aspart 100 unit per 1 ml NovoRapid Penfill 100units/ml solution for injection 3ml cartridges | 5 cartridge P £28.31 DT = £28.31 ▶NovoRapid PumpCart (Novo Nordisk Ltd) Insulin aspart 100 unit per 1 ml NovoRapid PumpCart 100units/ml solution for injection 1.6ml cartridges | 5 cartridge P £15.10 DT = £15.10 eiiii F 751

PDF page 775

Dose text by age group

Adult

Administer immediately before meals or when

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Adult

According to requirements

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Adult

Administer immediately before meals or when

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Adult

According to requirements

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Insulin aspart

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 774, 775

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 774

National Funding Access Decisions

PDF page 775

Safety

Interactions

→Appendix 1: insulins

PDF page 774

Side Effects

▶Common or very common Skin reactions ▶Uncommon Refraction disorder

PDF page 774

Pregnancy

Not known to be harmful—may be used during pregnancy.

PDF page 774

Breast Feeding

Not known to be harmful—may be used during lactation.

PDF page 774

Dose and formulations

Directions For Administration

PDF page 774

Medicinal Forms

PDF page 775

Dose text by age group

Adult

Administer immediately before meals or when

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Adult

According to requirements

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Adult

Administer immediately before meals or when

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Adult

According to requirements

First-line fragment. Read the complete Indications and Dose section above.

PDF page 774

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.